ETFs Beam Therapeutics Inc.




Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-07-12 pm EDT 5-day change 1st Jan Change
26.88 USD +3.86% Intraday chart for Beam Therapeutics Inc. +16.46% -1.25%
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
26.88 USD
Average target price
47.77 USD
Spread / Average Target
  1. Stock Market
  2. Equities
  3. BEAM Stock
  4. ETFs Beam Therapeutics Inc.